

OVERVIEW

Biodel Inc.

Founded: **December 2003**

Employees: **55**

Public: **May 2007**

NASDAQ: **BIOD**

As of July 1, 2010:

Share price: **\$3.68**

Market Cap: **\$126.8M**

Shares Outstanding: **23.9M**

Cash: **Q1 \$32.7M**

MANAGEMENT

Errol De Souza, PhD

President & CEO, Director

Dr. Solomon S. Steiner

Founder, CSO, Director

Mr. Gerard J. Michel

CFO, VP, Corporate Development and Treasurer

Dr. Alan S. Krasner

Chief Medical Officer

Mr. Paul Bavier

General Counsel and Corporate Secretary

ANALYST COVERAGE

Pamela Bassett ,DMD

Cantor Fitzgerald

Cory Kasimov

JP Morgan & Co.

Matthew Kaplan

Ladenburg Thalmann & Co.

Josh Schimmer

Leerink Swann LLC

John Newman

Oppenheimer & Co.

Liana Moussatos, PhD

Wedbush Morgan Securities

MISSION

At Biodel, we believe patients deserve better medicines to treat diabetes and its complications. Our goal is to design, develop and advance safe and effective medicines that make it easier for patients to manage their disease successfully. By combining our proprietary drug-delivery technology and unique expertise in diabetes drug development, we are working aggressively to meet this goal.

INNOVATION


Biodel is developing novel forms of insulin and other peptide hormones for use in treating diabetes and its complications, including hyperglycemia, hypoglycemia, cardiovascular complications and weight control.

Biodel's technology facilitates more natural absorption profiles than currently available products and appears to improve its therapeutic efficacy in patients with Type 1 and Type 2 diabetes.

Clinical studies have demonstrated that Biodel's lead insulin product candidate, VIAject® (*PDUFA 10/30/10*), may be delivered into the bloodstream faster than currently marketed insulins and with fewer side effects.

PIPELINE

We are building a pipeline of insulin- and other peptide hormone-based product candidates using our proprietary technology, scientific knowledge and clinical expertise in diabetes drug development.



Biodel Corporation is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Biodel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Biodel Corporation or its management. Biodel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

BOARD OF DIRECTORS

Charlie Sanders, MD
Chairman of the Board

Errol De Souza, PhD
President, CEO, Director

Dr. Solomon S. Steiner
Founder, CSO, Director

Donald M. Casey Jr.
Director

Barry Ginsberg, MD, PhD
Director

Dr. Ira W. Lieberman
Director

Dr. Brian Pereira
Director

Mr. Scott A. Weisman
Director

CONTACT INFORMATION

HEADQUARTERS

100 Saw Mill Road
Danbury, Connecticut 06810
(203) 796-5000 (tel)
(203) 796-5001 (fax)

www.biodel.com
shareholders@biodel.com

INVESTOR RELATIONS

THE TROUT GROUP, LLC
740 Broadway, Suite 903
NY, NY 10003
(646) 378-2952 (tel)

TRANSFER AGENT

Continental Stock Transfer
17 Battery Place
New York, NY 10004
Tel: (212) 509-4000 ext. 206
Fax: (212) 509-5150 fax
www.continentalstock.com
cstmail@continentalstock.com


DIABETES

Diabetes is a disease characterized by abnormally high levels of blood glucose and inadequate levels of insulin. Glucose is a simple sugar used by all the cells of the body to produce energy and support life.

UNMET NEED

Humans need a minimum level of glucose in their blood at all times to function and stay alive. Insulin is a peptide hormone naturally secreted by the pancreas to regulate the body's management of glucose. When a healthy individual begins a meal, the pancreas releases a natural spike of insulin, called the first-phase insulin release, which is critical to the body's overall control of glucose. Many patients with diabetes lack the first-phase insulin release and must treat themselves with daily meal-time insulin injections to avoid the negative effects of hyperglycemia and hypoglycemia.

Insulin: Physiologic Response and Replacement Therapy



This graph illustrates the first phase insulin release in a healthy individual as compared to an individual with poorly controlled diabetes.